SIRT1 and myeloid sarcoma: We have also shown that SIRT1 expression is reduced in peripheral blood mononuclear cells of MS patients during relapses and in those who do not respond to treatment with glatiramer acetate, a disease-modifying drug used for treating MS, suggesting that SIRT1 could serve as a biomarker of disease activity and patient responsiveness to therapy (15, 17).